New hope for tough myeloma: Two-Drug combo takes on relapsed High-Risk disease
NCT ID NCT06948084
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 38 times
Summary
This study tests whether a new two-drug combination (daratumumab and teclistamab) works better than standard three-drug combos for people with high-risk multiple myeloma that has returned or not responded to one prior treatment. About 80 adults will be randomly assigned to receive either the new combo or standard care. The main goal is to see if the new combo can make myeloma undetectable in the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.